company background image
RGEN logo

Repligen NasdaqGS:RGEN Stock Report

Last Price

US$125.32

Market Cap

US$6.7b

7D

-0.2%

1Y

-16.2%

Updated

21 Jun, 2024

Data

Company Financials +

Repligen Corporation

NasdaqGS:RGEN Stock Report

Market Cap: US$6.7b

RGEN Stock Overview

Develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.

RGEN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance1/6
Financial Health5/6
Dividends0/6

Repligen Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Repligen
Historical stock prices
Current Share PriceUS$125.32
52 Week HighUS$211.13
52 Week LowUS$110.45
Beta1.04
11 Month Change-24.11%
3 Month Change-36.72%
1 Year Change-16.21%
33 Year Change-34.60%
5 Year Change45.81%
Change since IPO1,122.63%

Recent News & Updates

Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Jun 14
Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Jun 10
Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Recent updates

Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Jun 14
Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Jun 10
Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Repligen Stock: Still Quite Overvalued

May 30

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

May 03
Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Apr 30
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Apr 15
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Feb 13
At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Jan 08
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

Dec 19
Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Nov 01
What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Oct 17
Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Sep 29
Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade

Aug 09
Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade

Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?

Jul 17
Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?

Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?

Jul 03
Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?

With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case

Jun 19
With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case

Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)

May 23
Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly

Apr 11
Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly

Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?

Mar 28
Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?

We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease

Mar 08
We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Feb 20
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly

Jan 10
Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly

Should You Think About Buying Repligen Corporation (NASDAQ:RGEN) Now?

Dec 28
Should You Think About Buying Repligen Corporation (NASDAQ:RGEN) Now?

Is Repligen (NASDAQ:RGEN) A Risky Investment?

Oct 03
Is Repligen (NASDAQ:RGEN) A Risky Investment?

Repligen: Now Best Biotech Nearby Cap-Gain Prospect

Sep 27

Shareholder Returns

RGENUS Life SciencesUS Market
7D-0.2%-0.09%0.5%
1Y-16.2%0.8%23.9%

Return vs Industry: RGEN underperformed the US Life Sciences industry which returned -0.5% over the past year.

Return vs Market: RGEN underperformed the US Market which returned 22.9% over the past year.

Price Volatility

Is RGEN's price volatile compared to industry and market?
RGEN volatility
RGEN Average Weekly Movement6.3%
Life Sciences Industry Average Movement6.8%
Market Average Movement5.7%
10% most volatile stocks in US Market15.4%
10% least volatile stocks in US Market2.8%

Stable Share Price: RGEN's share price has been volatile over the past 3 months.

Volatility Over Time: RGEN's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19811,783Tony Huntwww.repligen.com

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.

Repligen Corporation Fundamentals Summary

How do Repligen's earnings and revenue compare to its market cap?
RGEN fundamental statistics
Market capUS$6.71b
Earnings (TTM)US$14.84m
Revenue (TTM)US$607.45m

471.8x

P/E Ratio

11.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RGEN income statement (TTM)
RevenueUS$607.45m
Cost of RevenueUS$318.08m
Gross ProfitUS$289.37m
Other ExpensesUS$274.53m
EarningsUS$14.84m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.27
Gross Margin47.64%
Net Profit Margin2.44%
Debt/Equity Ratio29.6%

How did RGEN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.